{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:57:25Z","timestamp":1780563445041,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40263-024-01095-y","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T07:02:15Z","timestamp":1720681335000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022"],"prefix":"10.1007","volume":"38","author":[{"given":"Cl\u00e9ment","family":"Garnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-4698","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-6522","authenticated-orcid":false,"given":"Elisabeth","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-9673","authenticated-orcid":false,"given":"Thomas","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00e9tan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7172-7835","authenticated-orcid":false,"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"1095_CR1","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit\u202f: Lyrica [Internet]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220921157050\/anx_157050_fr.pdf"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ebiom.2019.03.047","volume":"42","author":"DS Reddy","year":"2019","unstructured":"Reddy DS. An enigmatic role of tonic inhibition in gabapentin therapy. EBioMedicine. 2019;42:14\u20135.","journal-title":"EBioMedicine"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","volume":"52","author":"G Zaccara","year":"2011","unstructured":"Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826\u201336.","journal-title":"Epilepsia"},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuropharm.2014.04.014","volume":"87","author":"MK Romach","year":"2014","unstructured":"Romach MK, Schoedel KA, Sellers EM. Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology. 2014;87:81\u201390.","journal-title":"Neuropharmacology"},{"key":"1095_CR5","unstructured":"Annual report on the state of the drugs problem in Europe - 2010 - EMCDDA [Internet]. Available from: https:\/\/www.emcdda.europa.eu\/publications\/annual-report\/2010_en"},{"key":"1095_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","volume":"69","author":"M Gahr","year":"2013","unstructured":"Gahr M, RolandW F, Hiemke C, K\u00f6lle MA, Sch\u00f6nfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"1095_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/JCP.0b013e318272864d","volume":"32","author":"D Carrus","year":"2012","unstructured":"Carrus D, Schifano F. Pregabalin Misuse-Related Issues; Intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"1095_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","volume":"66","author":"S Schwan","year":"2010","unstructured":"Schwan S, Sundstr\u00f6m A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin\u2014Results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947\u201353.","journal-title":"Eur J Clin Pharmacol"},{"key":"1095_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/bcp.13892","volume":"85","author":"D Driot","year":"2019","unstructured":"Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85:1260\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1095_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639780","volume":"12","author":"M Tambon","year":"2021","unstructured":"Tambon M, Pont\u00e9 C, Jouanjus E, Fouilh\u00e9 N, Micallef J, Lapeyre-Mestre M, et al. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry. 2021;12: 639780.","journal-title":"Front Psychiatry."},{"key":"1095_CR11","unstructured":"Pr\u00e9gabaline (Lyrica et g\u00e9n\u00e9riques)\u202f: modification des conditions de prescription et d\u00e9livrance pour limiter le m\u00e9susage [Internet]. Available from: https:\/\/ansm.sante.fr\/actualites\/pregabaline-lyrica-et-generiques-modification-des-conditions-de-prescription-et-delivrance-pour-limiter-le-mesusage"},{"key":"1095_CR12","unstructured":"Open Medic\u202f: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments interr\u00e9gimes [Internet]. Available from: https:\/\/www.data.gouv.fr\/fr\/datasets\/open-medic-base-complete-sur-les-depenses-de-medicaments-interregimes\/"},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000050711","volume":"7","author":"X Thirion","year":"2001","unstructured":"Thirion X, Micallef J, Barrau K, Djezzar S, Sanmarco JL, Lagier G. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM Programme. Eur Addict Res. 2001;7:32\u20136.","journal-title":"Eur Addict Res"},{"key":"1095_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/fcp.12024","volume":"27","author":"E Frauger","year":"2013","unstructured":"Frauger E, Moracchini C, Le Boisselier R, Braunstein D, Thirion X, Micallef J, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol. 2013;27:672\u201382.","journal-title":"Fundam Clin Pharmacol"},{"key":"1095_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00228-014-1783-x","volume":"71","author":"V Pauly","year":"2015","unstructured":"Pauly V, Lapeyre-Mestre M, Braunstein D, Rueter M, Thirion X, Jouanjus E, et al. Detection of signals of abuse and dependence applying disproportionality analysis. Eur J Clin Pharmacol. 2015;71:229\u201336.","journal-title":"Eur J Clin Pharmacol"},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","volume":"72","author":"E Frauger","year":"2017","unstructured":"Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, et al. Dispositif pharmaco\u00e9pid\u00e9miologique de surveillance des substances psychoactives\u202f: int\u00e9r\u00eats du programme national OPPIDUM du R\u00e9seau fran\u00e7ais d\u2019addictovigilance. Therapies. 2017;72:491\u2013501.","journal-title":"Therapies"},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","volume":"74","author":"J Micallef","year":"2019","unstructured":"Micallef J, Jouanjus \u00c9, Mallaret M, Lapeyre MM. D\u00e9tection des signaux du r\u00e9seau fran\u00e7ais d\u2019addictovigilance\u202f: m\u00e9thodes innovantes d\u2019investigation, illustrations et utilit\u00e9 pour la sant\u00e9 publique. Therapies. 2019;74:579\u201390.","journal-title":"Therapies"},{"key":"1095_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/fcp.12738","volume":"36","author":"RG Dumonceau","year":"2022","unstructured":"Dumonceau RG, Soeiro T, Lacroix C, Giocanti A, Frauger \u00c9, Mezaache S, et al. Antidepressants abuse in subjects with opioid use disorders: a 10-year study in the French OPPIDUM program. Fundamemntal Clin Pharma. 2022;36:436\u201342.","journal-title":"Fundamemntal Clin Pharma."},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2515\/therapie\/2012064","volume":"67","author":"C Moracchini","year":"2012","unstructured":"Moracchini C, Frauger E, Pauly V, Nordmann S, Thirion X, Micallef J. Les CAARUD, lieux privil\u00e9gi\u00e9s d\u2019\u00e9mergence de signaux pour l\u2019addictovigilance. Therapies. 2012;67:437\u201345.","journal-title":"Therapies"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.encep.2009.03.011","volume":"36","author":"V Pauly","year":"2010","unstructured":"Pauly V, Frauger E, Rouby F, Sirere S, Monier S, Paulet C, et al. \u00c9valuation des conduites addictives chez les personnes entrant en milieu p\u00e9nitentiaire \u00e0 partir du programme OPPIDUM du r\u00e9seau des centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance (CEIP). L\u2019Enc\u00e9phale. 2010;36:122\u201331.","journal-title":"L\u2019Enc\u00e9phale."},{"key":"1095_CR21","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV-TR)."},{"key":"1095_CR22","unstructured":"Code de la Sant\u00e9 Publique, article R5132-97 [Internet]. Available from: https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000039659171"},{"key":"1095_CR23","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2023. Available from: https:\/\/www.R-project.org\/"},{"key":"1095_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P. MissForest\u2014Non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28:112\u20138.","journal-title":"Bioinformatics"},{"key":"1095_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern applied statistics with S","author":"WN Venables","year":"2002","unstructured":"Venables WN, Ripley BD. Modern applied statistics with S. 4th ed. New York: Springer; 2002.","edition":"4"},{"key":"1095_CR26","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1111\/bcp.15323","volume":"88","author":"A Roussin","year":"2022","unstructured":"Roussin A, Soeiro T, Fouque C, Jouanjus E, Frauger E, Fouilh\u00e9 N, et al. Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data. Brit J Clin Pharma. 2022;88:3789\u2013802.","journal-title":"Brit J Clin Pharma."},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/fcp.12603","volume":"35","author":"C Eiden","year":"2021","unstructured":"Eiden C, Vincent M, Serrand C, Serre A, Richard N, Picot M, et al. Health consequences of cocaine use in France: data from the French Addictovigilance Network. Fundamemntal Clin Pharma. 2021;35:455\u201365.","journal-title":"Fundamemntal Clin Pharma."},{"key":"1095_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","volume":"45","author":"J Perri-Pland\u00e9","year":"2022","unstructured":"Perri-Pland\u00e9 J, Miremont-Salam\u00e9 G, Micallef J, Herman C, Baumevieille M, Abriat F, et al. A 13-year national monitoring study to assess narcotic prescriptions and indications (2007\u20132019). Drug Saf. 2022;45:37\u201344.","journal-title":"Drug Saf"},{"key":"1095_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40263-017-0467-3","volume":"31","author":"BJ Snellgrove","year":"2017","unstructured":"Snellgrove BJ, Steinert T, Jaeger S. Pregabalin use among users of illicit drugs: a cross-sectional survey in Southern Germany. CNS Drugs. 2017;31:891\u20138.","journal-title":"CNS Drugs"},{"key":"1095_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","volume":"43","author":"S H\u00e4gg","year":"2020","unstructured":"H\u00e4gg S, J\u00f6nsson AK, Ahlner J. Current Evidence on Abuse and Misuse of Gabapentinoids. Drug Saf. 2020;43:1235\u201354.","journal-title":"Drug Saf"},{"key":"1095_CR31","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1111\/add.15970","volume":"117","author":"B Murnion","year":"2022","unstructured":"Murnion B, Schaffer A, Cairns R, Brett J. Gabapentinoids: repeating mistakes of the past? Addiction. 2022;117:2969\u201371.","journal-title":"Addiction"},{"key":"1095_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/fcp.12726","volume":"36","author":"M Chappuy","year":"2022","unstructured":"Chappuy M, Nourredine M, Clerc B, Fahmi M, Misslin P, Berthier M, et al. Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016\u20131Q2021. Fundamemntal Clin Pharma. 2022;36:448\u201352.","journal-title":"Fundamemntal Clin Pharma."},{"key":"1095_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225189","volume":"14","author":"M Rousselet","year":"2019","unstructured":"Rousselet M, Guerlais M, Caillet P, Le Geay B, Mauillon D, Serre P, et al. Consumption of psychoactive substances in prison: Between initiation and improvement, what trajectories occur after incarceration? COSMOS study data. PLoS ONE. 2019;14: e0225.","journal-title":"PLoS ONE"},{"key":"1095_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3399\/bjgp13X670615","volume":"63","author":"M Bicknell","year":"2013","unstructured":"Bicknell M. The pain of pregabalin prescribing in prisons. Br J Gen Pract. 2013;63:405.","journal-title":"Br J Gen Pract"},{"key":"1095_CR35","first-page":"199","volume":"49","author":"D Marcot","year":"2023","unstructured":"Marcot D, Castelan Camargo HC. Pr\u00e9gabaline sous la loupe carc\u00e9rale. R\u00e9flexions sur une probl\u00e9matique \u00e9mergente L\u2019Enc\u00e9phale. 2023;49:199\u2013201.","journal-title":"R\u00e9flexions sur une probl\u00e9matique \u00e9mergente. L\u2019Enc\u00e9phale."},{"key":"1095_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5694\/mja2.50398","volume":"211","author":"G Nicholls","year":"2019","unstructured":"Nicholls G, Samios P, Hampton S. Management of pregabalin and gabapentin prescribing and use in NSW prisons. Med J Australia. 2019;211:474.","journal-title":"Med J Australia."},{"key":"1095_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000321079","volume":"80","author":"F Schifano","year":"2011","unstructured":"Schifano F, D\u2019Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118\u201322.","journal-title":"Psychother Psychosom"},{"key":"1095_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","volume":"28","author":"F Schifano","year":"2014","unstructured":"Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491\u20136.","journal-title":"CNS Drugs"},{"key":"1095_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.therap.2016.04.006","volume":"71","author":"D Driot","year":"2016","unstructured":"Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapies. 2016;71:575\u20138.","journal-title":"Therapies"},{"key":"1095_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/02791072.2021.2013579","volume":"54","author":"L Langlum\u00e9","year":"2022","unstructured":"Langlum\u00e9 L, Eiden C, Roy S, Taruffi F, Gambier J, Donnadieu-Rigole H, et al. Management of pregabalin use disorder: a case series. J Psychoactive Drugs. 2022;54:386\u201391.","journal-title":"J Psychoactive Drugs"},{"key":"1095_CR41","unstructured":"Usage de drogues et conditions de vie des \u201cmineurs non accompagn\u00e9s\u201d - OFDT [Internet]. Available from: https:\/\/www.ofdt.fr\/BDD\/publications\/docs\/eisxcg2ca.pdf"},{"key":"1095_CR42","doi-asserted-by":"crossref","unstructured":"Dufayet L, Care W, Deheul S, Laborde-Casterot H, Nisse P, French PCC Research Group, et al. Increase in pregabalin recreational use in adolescents in France. Clin Toxicol. 2021;59:1027\u201330.","DOI":"10.1080\/15563650.2021.1892719"},{"key":"1095_CR43","doi-asserted-by":"publisher","first-page":"S658","DOI":"10.1192\/j.eurpsy.2023.1368","volume":"66","author":"C Portela","year":"2023","unstructured":"Portela C, Oliveira C, Gon\u00e7alves M. Prescription drug abuse in migrants from Middle Eastern and North African countries: a review. Eur Psychiatr. 2023;66:S658\u20139.","journal-title":"Eur Psychiatr"},{"key":"1095_CR44","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/add.16261","volume":"118","author":"T Soeiro","year":"2023","unstructured":"Soeiro T, Pradel V, Lapeyre-Mestre M, Micallef J. Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: a nation-wide, repeated cross-sectional study. Addiction. 2023;118:1984\u201393.","journal-title":"Addiction"}],"updated-by":[{"DOI":"10.1007\/s40263-024-01119-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01095-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01095-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01095-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:29:52Z","timestamp":1725028192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01095-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01095-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-024-01119-7","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"2 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-024-01119-7","URL":"https:\/\/doi.org\/10.1007\/s40263-024-01119-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The OPPIDUM program collects only anonymous data. No ethics approval is requested to process anonymous data according to the French law.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data are not publicly available due to privacy or ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J.M. and G.G. were responsible for study conception. C.L. coordinates the OPPIDUM program. E.J. and C.L. extracted the data. C.G. and M.S. contributed to the data quality assessment and the literature review. E.J. and T.S. performed the statistical analysis. C.G., M.S., E.J., M.L.M., and J.M. interpreted the data. C.L., G.G., and J.M. supervised the work. C.G., M.S., C.L., T.S., and J.M. drafted the manuscript. All authors reviewed and approved the final manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}